CompletedPhase 2

Cardiac Allograft Vasculopathy Inhibition With Alirocumab

United States114 participantsStarted 2019-05-13

Plain-language summary

The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Heart Transplant recipient Exclusion Criteria: * impaired liver function

What they're measuring

Change in volume of plaque at 1 year post study drug start post heart transplant

Timeframe: Baseline and one year

Trial details

NCT IDNCT03537742

SponsorStanford University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07-11

View on ClinicalTrials.gov More Vasculopathy trials